Eliem Therapeutics to Participate at Four Upcoming Investor Conferences
November 04, 2021 07:00 ET
|
Eliem Therapeutics, Inc.
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal...
Eliem Therapeutics Reports Second Quarter Financial Results
September 13, 2021 16:10 ET
|
Eliem Therapeutics, Inc.
On track to advance two clinical programs through five proof-of-concept trials and progress two preclinical programs over the next 18-24 months Recently completed an IPO for $92 million in gross...
Eliem Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
August 12, 2021 21:06 ET
|
Eliem Therapeutics, Inc.
SEATTLE and CAMBRIDGE, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for...
Eliem Therapeutics Announces Pricing of Initial Public Offering
August 09, 2021 22:33 ET
|
Eliem Therapeutics, Inc.
SEATTLE and CAMBRIDGE, United Kingdom, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal...